Sign in Get iMD Health

Prostate Cancer Canada partnership provides easy access to resources

September is Prostate Cancer Awareness Month, a fitting time for a new partnership between iMD Health Global and Prostate Cancer Canada


Sept 17, 2019 – Toronto, ON

Every day 62 men are diagnosed with prostate cancer in Canada1

Prostate cancer is the most commonly diagnosed cancer among Canadian men and accounts for 20% of all new cancer cases across the country1. Over the past 25 years, Prostate Cancer Canada has invested $120 million into research and contributed to increased public awareness and a 50% reduction in mortality rate from prostate cancer.

Progress towards the eradication of prostate cancer has been made, but Prostate Cancer Canada has not slowed down the pursuit of its goal to turn awareness into action in order to save the lives of Canadian men, and improve those of men and their families already living with a diagnosis. Prostate Cancer Canada’s partnership with iMD Health will promote these goals by giving healthcare providers immediate access to Prostate Cancer Canada’s invaluable educational resources, via the iMD Patient Engagement Platform.

Visual-based education & engagement “At the Point of Care”

The iMD Platform is Canada’s largest digital library of patient-friendly health resources provided by trusted partners including over 60 North American health associations and the world-renowned Mayo Clinic. The web-based platform is a tool for healthcare providers to visually educate and engage patients during consultation using iMD’s 50,000+ health resources organized across 1,800 medical conditions and procedures.

Studies have shown that patients are much more likely to remember important details from discussions about their health when visual resources such as images, diagrams and videos are used to help explain often-complex medical topics.

Getting tested is easy and could be the difference between life and death

“If prostate cancer is detected early, the survival rate is close to 100%. But if detected late, 3 of 4 men will die,” says Peter Coleridge, President and CEO of Prostate Cancer Canada. “That’s why giving men information to speak with their doctor about an early detection strategy is key. Prostate Cancer Canada’s patient materials educate men on how and when to get tested, as well as coping and lifestyle tips for those living with the disease. We’re glad they are being made accessible on the iMD Platform to healthcare providers across Canada.”

iMD Health and Prostate Cancer Canada encourage iMD users to share these resources with patients who are at risk of developing prostate cancer in order to facilitate discussions around PSA testing – a simple blood test that measures the levels of prostate specific antigen (PSA) protein in a patient’s blood.

“iMD Health and Prostate Cancer Canada share the goals of improving patients’ health literacy and treatment outcomes. Our partnership will improve the lives of Canadian men facing a potential prostate cancer diagnosis by providing crucial educational resources where and when they need them most:  during conversations with trusted healthcare providers,” says Jared Sonnenberg, Vice President of iMD Health.

“What better way to inform men of the risks and engage them in continued monitoring and healthy living than through iMD-powered conversations in clinic or pharmacy environments.”

To learn more about Prostate Cancer Canada, visit www.prostatecancer.ca.

To learn more about iMD Health, visit www.imdhealth.com.

Canadian healthcare providers can sign up to use iMD’s platform free at app.imdhealth.com/signup.

For more information, please contact:

Jared Sonnenberg, VP of iMD Health

jared.sonnenberg@imdhealth.com

1 Canadian Cancer Society, 2019